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pre-existing coronary lesion, yet act on newly formed
lesions—we simply don’t know.
As the power of the study was not sufﬁcient to render the
coronary end point statistically signiﬁcant, it is wise to state
that the currently available data do not allow to draw deﬁnite
conclusions regarding the efﬁcacy of statins on coronary
death in hemodialyzed patients. Absence of evidence is not
necessarily evidence of absence. We have to wait for the
outcome of the SHARP study to know the deﬁnite answer.7
The conclusion that statins are ineffective in dialyzed
patients is certainly not strictly proven and cannot be
answered conclusively today. Admittedly, it is possible that
coronary heart disease in terminal renal disease differs from
coronary heart disease in nonrenal patients and is resistant to
statin treatment as suggested by some previous observa-
tions8,9—but a Socratic attitude demands to admit that
currently we simply don’t know the answer.
We believe that at the current state of our ignorance it is
wise to continue with statins in patients who had been on
statins before dialysis, and, in view of their encouraging side-
effect proﬁle, to administer statins (admittedly without the
deﬁnite evidence) at least in dialysis patients with clinically
proven coronary heart disease.
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The Authors Reply: Ritz and Wanner1 provide insightful
remarks about the need to understand the limitations of
evidence from trials before applying the results in practice. In
our study, statin use in dialysis patients continued to rise
despite the results of the 4D study.2,3 We wish to emphasize
that the purpose of our study was not to applaud or criticize
physicians in their continued use of statins. We agree that
although the evidence from the 4D and AURORA studies
seem to suggest a lack of beneﬁt, the limitations of those trials
make the results less conclusive than they could be.4 Given
the resources needed to conduct randomized trials, it is vital
that they contribute to scientiﬁc knowledge without ambi-
guity. The availability of funds is a major challenge to
conducting trials of common cardiovascular medications.
Industries may be less interested in ﬁnancing these trials, as
dialysis patients represent a small proportion of the overall
market sales. Yet, our need for such evidence remains high, as
renal patients were frequently excluded from trials that
inﬂuenced the use of these medications in the general
population.5 The main purpose of our study was to explore
the translation of knowledge in renal practice. Our discussion
offers several explanations as to why physicians continued to
prescribe statins after the 4D study, which includes
uncertainty about the overall result. As Ritz and Wanner
point out, the SHARP trial will provide more information
about the effectiveness of statins in renal patients.6 We await
these results to guide the care of our patients.
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Very low blood pH is life
threatening
To the Editor: In the review ‘assessing acid–base disorders’,
Adrogue´ et al.1 have discussed the usefulness of three
approaches to assess acid–base disorders with the ﬁnal aim
‘to undertake appropriate intervention’ (p 1239). However,
they have omitted to discuss the importance of blood pH
per se (i.e., the concentration of hydrogen ions (Hþ ) in the
blood).
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